WELCOME to the new EUnetHTA website!
EUnetHTA is delighted to welcome you to our new website with a brand new structure and design marking the transition from EUnetHTA Joint Action 1 to EUnetHTA Joint Action 2. On this website you have many possibilities of staying informed on the EUnetHTA history, activities and important news. By clicking on “about us” you can […]
The EVIDENT Database is now launched
EUnetHTA is pleased to announce the release of the Evidence Database on New Technologies (EVIDENT) produced within Work Package 7 as its third Joint Action 1 deliverable. Access to the database is now available to all EUnetHTA Partners and Associates via the following link: https://evident.has-sante.fr/has/login.xhtml. The EVIDENT Database enables sharing early information on evidence gaps identified […]
The criteria to select and prioritise health technologies for additional evidence generation is now published
EUnetHTA Work Package 7 is pleased to present its 2nd deliverable for Joint Action 1: The criteria to select and prioritise health technologies for additional evidence generation. Selection/prioritization criteria are intended to help HTA doers, funders and other stakeholders select, among new technologies, the ones for which complementary studies are really worth performing. The document […]
EUnetHTA Strategy 2012 and beyond
The EUnetHTA Strategy 2012 and beyond is now published The EUnetHTA Plenary Assembly has endorsed the EUnetHTA strategy laying down the objectives and priorities of its activities during the next few years. The more focused vision, mission and values were specifically agreed and approved by the EUnetHTA Partners. The strategy takes into account current efforts of the Members States […]
EUnetHTA Joint Action 2 starts on October 1, 2012
The EUnetHTA Joint Action 2 Grant Agreement has been signed by the EU Executive Agency for Health and Consumers and the Coordinator (Danish Health and Medicines Authority) on behalf of 37 partners in 26 EU Member States, Croatia and Norway to start its activities on October 1, 2012. For the next 3 years EUnetHTA will […]
European Commission launches stakeholder consultation
The European Commission launched stakeholder consultation on modalities of stakeholder involvement in the future voluntary HTA network (Directive 2011/24/EU). During a consultation period until August 1, 2012 it aims to receive contributions from a wide range of stakeholder groups and the public authorities and government-appointed bodies responsible for commissioning or executing HTA reports. For more […]
EUnetHTA is conducting a pilot by WP5
EUnetHTA is conducting a pilot by WP5, Relative Effectiveness Assessment (REA) of Pharmaceuticals, in which the draft tools that are being developed for relative effectiveness assessment of pharmaceuticals are tested. The first draft version of the report (rapid assessment of pazopanib for the treatment of advanced renal cell cancer) was ready in November 2011 and […]
An article on SCRIPT about HTA and EUnetHTA
An article on SCRIPT about HTA and EUnetHTA Information about EUnetHTA under an article about current Health Technology Assessment in EU countries is available here. Please also visit www.scripintelligence.com
The Policy for the HTA Core Model® and core HTA information is now available
WP4 is pleased to announce that the Policy for the HTA Core Model® and core HTA information is now available. This document defines the EUnetHTA policy to steer the utilisation and further development of the new HTA production and sharing framework, the HTA Core Model®. The policy is divided into five sections (A-E) that consider […]
The EU Commission’s view on HTA
EUnetHTA conference held in Gdansk, Poland on December 8-9, 2011, was attended by the European Commissioner for Health and Consumer Protection, John Dalli, who expressed the Commission aims at enhancing the cooperation between the EU Member States in the field of HTA. The Commission is currently working on a joint initiative, a joint action under […]
